What Clinicians Need to Know About the J&J Vaccine Pause

Apr 13, 2021

COVID-19 Announcement: Nurse-Led COVID Vaccine Confidence Project

The CDC and FDA are recommending a pause in use of the Johnson & Johnson (J&J) COVID-19 vaccine after six reported U.S. cases of a rare and severe type of blood clot in individuals after receiving the J&J vaccine and in order to prepare the health care system to recognize and treat patients appropriately, to report severe events they may be seeing in people who have received the J&J vaccine. CDC will convene a meeting of the Advisory Committee on Immunization Practices (ACIP) on Wednesday, April 14, from 1:30 - 4:30pm Eastern Time to further review these cases and assess their potential significance.

 Click here to access the 4/14 ACIP Meeting 


What we know now

(last updated 4/13/2021)

  • 6 women developed blood clots within 6-13 days after receiving the Johnson & Johnson vaccine
  • 7 million doses of the Johnson & Johnson vaccine have been administered in the U.S.
  • Risk of blood clots appears to be extremely rare
  • The CDC expects the pause to last several days

What you can tell your patients

  • For people who received the J&J vaccine more than a month ago: "The risk for developing blood clots is very low."
  • For people who received the J&J vaccine within the last few weeks (mid-March to mid-April): "Be aware of the symptoms of blood clots. If you experience severe headaches, abdominal pain, leg pain, or shortness of breath you should immediately seek emergency medical treatment and tell the doctors you received the Johnson & Johnson vaccine."
  • For people who received the Pfizer or Moderna vaccines: "There is no known risk of blood clots for these vaccines."



Stay Connected with Nurse-Led Care